BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 8393820)

  • 1. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.
    Rauscher FJ
    FASEB J; 1993 Jul; 7(10):896-903. PubMed ID: 8393820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wilms tumor and the WT1 gene.
    Lee SB; Haber DA
    Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
    Park S; Tomlinson G; Nisen P; Haber DA
    Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
    Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
    Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion.
    Bardeesy N; Zabel B; Schmitt K; Pelletier J
    Genomics; 1994 Jun; 21(3):663-4. PubMed ID: 7959750
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors.
    Iben S; Royer-Pokora B
    Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype/phenotype correlations in Wilms' tumor.
    Huff V
    Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilateral Wilms tumor in a boy with severe hypospadias and cryptochidism due to a heterozygous mutation in the WT1 gene.
    Köhler B; Schumacher V; Schulte-Overberg U; Biewald W; Lennert T; l'Allemand D; Royer-Pokora B; Grüters A
    Pediatr Res; 1999 Feb; 45(2):187-90. PubMed ID: 10022588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
    Zhang X; Xing G; Saunders GF
    Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of Wilms' tumor genes.
    Hirose M
    J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical presentation of Denys-Drash syndrome in a female with a novel Wt1 gene mutation.
    Machin GA
    Birth Defects Orig Artic Ser; 1996; 30(1):269-86. PubMed ID: 9125334
    [No Abstract]   [Full Text] [Related]  

  • 13. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
    Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
    Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
    Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of the remaining allele of the WT1 gene in a Wilms' tumour from a WAGR patient.
    Brown KW; Watson JE; Poirier V; Mott MG; Berry PJ; Maitland NJ
    Oncogene; 1992 Apr; 7(4):763-8. PubMed ID: 1314370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
    Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
    Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the cellular protein encoded by the human Wilms' tumor (WT1) gene.
    Telerman A; Dodemont H; Degraef C; Galand P; Bauwens S; Van Oostveldt P; Amson RB
    Oncogene; 1992 Dec; 7(12):2545-8. PubMed ID: 1334252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
    McCoy C; McGee SB; Cornwell MM
    Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
    Hewitt SM; Hamada S; McDonnell TJ; Rauscher FJ; Saunders GF
    Cancer Res; 1995 Nov; 55(22):5386-9. PubMed ID: 7585606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein.
    Wang ZY; Qiu QQ; Gurrieri M; Huang J; Deuel TF
    Oncogene; 1995 Mar; 10(6):1243-7. PubMed ID: 7700651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.